Edwards Lifesciences CVP Daniel Lippis sells $53k in stock
Edwards Lifesciences executive Daniel Lippis recently sold a portion of the company's stock, totaling $53,017. The transactions were conducted under a pre-approved trading plan on October 8, 2026. Lippis sold 619 shares at $85.65 per share, while simultaneously exercising 619 stock options, which were set to expire on May 6, 2027.
Following the sale, Lippis still holds a total of 40,033.9103 shares of Edwards Lifesciences directly. The medical device company, valued at $48.6 billion, currently trades at $84.24, slightly below the insider's sale price. Analytical firm InvestingPro considers Edwards Lifesciences undervalued, citing its strong gross profit margin of 78% and 14.6% revenue growth over the last year.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
